Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ana.25759 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.
Pharmaceuticals (Basel)
December 2024
Life Molecular Imaging GmbH, Tegeler Str. 7, 13353 Berlin, Germany.
Florbetaben (FBB) is a radiopharmaceutical approved by the FDA and EMA in 2014 for the positron emission tomography (PET) imaging of brain amyloid deposition in patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. Initially, the clinical adoption of FBB PET faced significant barriers, including reimbursement challenges and uncertainties regarding its integration into diagnostic clinical practice. This review examines the progress made in overcoming these obstacles and describes the concurrent evolution of the diagnostic landscape.
View Article and Find Full Text PDFEnhancing Amyloid PET Quantification: MRI-Guided Super-Resolution Using Latent Diffusion Models.
Life (Basel)
December 2024
School of Computing and Augmented Intelligence, Arizona State University, Tempe, AZ 85281, USA.
Amyloid PET imaging plays a crucial role in the diagnosis and research of Alzheimer's disease (AD), allowing non-invasive detection of amyloid-β plaques in the brain. However, the low spatial resolution of PET scans limits the accurate quantification of amyloid deposition due to partial volume effects (PVE). In this study, we propose a novel approach to addressing PVE using a latent diffusion model for resolution recovery (LDM-RR) of PET imaging.
View Article and Find Full Text PDFAssociations of plasma biomarkers with cerebral perfusion and structure in Alzheimer's disease.
Transl Psychiatry
January 2025
Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
Plasma biomarkers have great potential in the screening, diagnosis, and monitoring of Alzheimer's disease (AD). However, findings on their associations with cerebral perfusion and structural changes are inconclusive. We examined both cross-sectional and longitudinal associations between plasma biomarkers and cerebral blood flow (CBF), gray matter (GM) volume, and white matter (WM) integrity.
View Article and Find Full Text PDFThe cerebral blood flow response to neuroactivation is reduced in cognitively normal men with β-amyloid accumulation.
Alzheimers Res Ther
January 2025
Functional Imaging Unit, Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Valdemar Hansens Vej 1-23, Glostrup, 2600, Denmark.
Background: Accumulation of β-amyloid (Aβ) in the brain is a hallmark of Alzheimer's Disease (AD). Cerebral deposition of Aβ initiates deteriorating pathways which eventually can lead to AD. However, the exact mechanisms are not known.
View Article and Find Full Text PDFIntroduction: Previous studies have examined the predictive accuracy of plasma amyloid beta (Aβ) biomarkers in clinical cohorts. However, their accuracy for predicting amyloid-positive patients in community-based cohorts is unclear. This study aimed to determine the predictive accuracy of Aβ precursor protein 669-711/Aβ1-42, Aβ1-40/1-42 and their composite biomarkers for brain amyloid deposition or the clinical progression in community-dwelling older adults with mild cognitive impairment (MCI).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!